Latest News
Biogen and Ionis Release Community Statement on NDA Filing Completion
Biogen and Ionis Pharmaceuticals have provided the following community statement regarding the the completion of their NDA filing for nusinersen. Dear members of the SMA community, Today we have achieved […]
Read More ›Biogen Completes Rolling Submission of New Drug Application to FDA
Biogen and Ionis today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of […]
Read More ›Roche Launches New Phase 2 Clinical Trials
Roche has officially launched two Phase 2 clinical trials testing RO7034067 (also known as RG7916). The trials will begin recruitment in October. Earlier this month, Roche first announced plans to […]
Read More ›Catch Up on Research News from the 2016 Family Friendly Research Poster Session
Over the last decade, we’ve seen many advances in spinal muscular atrophy research, from new techniques in gene therapy to drugs that show promise in slowing or stopping the progress […]
Read More ›Roche Provides New Update on Clinical Development of RG7916
Roche, PTC Therapeutics, and the SMA Foundation have released a community update on the development of their SMN2 splicing modifier clinical development program: Dear SMA community, Roche, together with our […]
Read More ›2016 SMA Researcher Meeting Summary: Regulation of SMN Protein Expression and Function
The SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA. This year we had a record setting 350 attendees. The goal of the meeting […]
Read More ›